Latest Conference Articles

December 6th 2018, 12:45am

San Antonio Breast Cancer Symposium

Adjuvant treatment with capecitabine in patients with early-stage triple-negative breast cancer did not significantly improve disease-free or overall survival compared with observation, according to results from the phase III GEICAM/CIBOMA trial that were presented at the 2018 San Antonio Breast Cancer Symposium.

December 6th 2018, 12:01am

San Antonio Breast Cancer Symposium

Ado-trastuzumab emtansine reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy.

December 5th 2018, 3:26am

ASH Annual Meeting and Exposition

The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.

December 5th 2018, 3:10am

ASH Annual Meeting and Exposition

A multitude of BCMA-targeted CAR T-cell therapies are currently in development, each demonstrating different efficacy and safety profiles and each with different constructs.

December 4th 2018, 8:34pm

ASH Annual Meeting and Exposition

A newly discovered recurrent mutation in the B-cell leukemia/lymphoma 2 protein mediates clinical resistance to venetoclax in patients with chronic lymphocytic leukemia.

December 4th 2018, 8:33pm

ASH Annual Meeting and Exposition

The triplet of daratumumab, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 44% compared with lenalidomide plus dexamethasone in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant.

December 4th 2018, 8:33pm

ASH Annual Meeting and Exposition

Rivaroxaban may significantly reduce venous thromboembolism occurrence among patients actively being treated with systemic therapy, according to results from the phase IIIb CASSINI trial.

December 4th 2018, 8:33pm

ASH Annual Meeting and Exposition

Patients with relapsed/refractory chronic lymphoblastic leukemia treated with single-agent venetoclax attained high rates of minimal residual disease in peripheral blood and bone marrow.

December 4th 2018, 8:32pm

ASH Annual Meeting and Exposition

The combination of ibrutinib and rituximab significantly improved overall survival and progression-free survival compared with standard fludarabine, cyclophosphamide, and rituximab for younger patients with chronic lymphocytic leukemia.

December 4th 2018, 8:17am

ASH Annual Meeting and Exposition

A Selinexor combination regimen induced an overall response rate of 26.2% in heavily pretreated patients with penta-refractory multiple myeloma.

December 4th 2018, 7:42am

ASH Annual Meeting and Exposition

Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.

December 4th 2018, 7:39am

ASH Annual Meeting and Exposition

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses initial results from a phase I clinical trial of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in patients with multiple myeloma during the 2018 ASH Annual Meeting.

December 4th 2018, 5:15am

ASH Annual Meeting and Exposition

Axicabtagene ciloleucel elicited a 2-year overall survival rate of 51% in patients with refractory large B cell lymphoma, representing a clear plateau in the survival curve.

December 4th 2018, 4:42am

ASH Annual Meeting and Exposition

The overall survival benefit with quizartinib in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia was observed across patient subgroups and reproduced consistently across sensitivity analyses.

December 4th 2018, 3:25am

ASH Annual Meeting and Exposition

The first-line combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) was associated with a 77% reduction in the risk for disease progression or death compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

December 4th 2018, 1:02am

ASH Annual Meeting and Exposition

Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma shows that responses are durable with no new safety signals observed.

December 3rd 2018, 10:19pm

ASH Annual Meeting and Exposition

The R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

December 3rd 2018, 9:29pm

ASH Annual Meeting and Exposition

The addition of a CD79b-targeted antibody-drug conjugate to bendamustine and rituximab more than doubled overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma.

December 3rd 2018, 8:41pm

ASH Annual Meeting and Exposition

More than 70% of older patients ineligible for intensive chemotherapy for acute myeloid leukemia had complete responses to venetoclax combined with hypomethylating agents, preliminary results from clinical trials have shown.

December 3rd 2018, 10:10am

ASH Annual Meeting and Exposition

The anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.